<?xml version="1.0" encoding="UTF-8"?>
<p>Costs and effects were discounted at 3%, and costs were assessed in 2017 US$ from a health sector perspective, which included the cost of treatment. Other than specifying a finite time horizon, all other aspects of the cost-effectiveness analysis were conducted in line with recommendations by the Panel on Cost-Effectiveness in Health and Medicine.[
 <xref rid="pone.0215965.ref044" ref-type="bibr">44</xref>] The simulated population was HIV-infected and uninfected New Yorkers from the start of the calibration (1997) up through 20 years after the intervention implementation in the year 2015.
</p>
